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when data were analyzed on the basis of the AGT and AT1Genetic polymorphism of the renin-angiotensin system and
genotypes, respectively. Potentially unfavorable combinationsorgan damage in essential hypertension.
of genotypes were also investigated by K-means cluster analy-Background. The renin-angiotensin-aldosterone system
sis. Two subgroups of patients were identified (cluster 1, N 5(RAAS) plays a significant role in the development of hyper-
70; cluster 2, N 5 57), and each differed significantly withtensive cardiac and vascular remodeling. Recently, several ge-
netic variants of its key components, which may be clinically regards to the presence and degree of TOD and patterns of
relevant and thus prove to be useful in the evaluation of cardio- RAAS gene polymorphisms (F, 15.97 for ACR; F, 7.19 for
vascular risk, have been described. We therefore investigated IMT; F, 217.03 for LVMI; F, 3.91 for ACE; F, 4.06 for AGT;
the association between ACE I/D, AGT M235T, and AT1 and F, 5.22 for AT1; df 1 to 214, P , 0.02, for each one of the
A1266C gene polymorphisms and early signs of target organ variables examined).
damage in 215 untreated patients with essential hypertension Conclusion. The D allele of the ACE gene may be an inde-
(EH). pendent risk factor for the development of target organ dam-
Methods. Genotyping was based on the polymerase chain age, and evaluating it could be useful for assessing cardiovascular
reaction technique, with further restriction analysis when re- risk in EH. Unfavorable patterns of RAAS genotypes seem to
quired. Albuminuria was measured as the albumin-to-creati- predispose patients to subclinical cardiovascular disease in EH.
nine ratio (ACR). The left ventricular mass index (LVMI) was
assessed by echocardiography (LVH 5 LVMI $ 125 g/m2),
carotid wall thickness (IMT) by an ultrasonographic (US) scan,
Genetic variants of several key components of theand retinal vascular changes by direct ophthalmoscopy (Keith–
Wagener classification). renin-angiotensin-aldosterone system (RAAS) have been
Results. The prevalence of microalbuminuria (Mi), LVH, described [1–3], which may be biologically and clinically
and retinal vascular changes was 14, 46, and 74%, respectively. relevant and, by means of various mechanisms, may in-ACE, AGT, and AT1 genotype distribution was in agreement
fluence the activity of the system both at the circulatorywith the Hardy–Weinberg equilibrium. There was no differ-
ence in age, duration of disease, body mass index (BMI), blood and tissue levels. In particular, an insertion/deletion (I/D)
pressure, and lipid profile when data were analyzed on the basis polymorphism in intron 16 of the angiotensin-converting
of genotype. Serum levels of angiotensin-converting enzyme enzyme (ACE) gene is strongly associated with plasma
(ACE) were related to the ACE genotype (10.2 6 0.5, DD;
and cellular ACE levels [2, 4] and has been suggested8.2 6 0.3, ID; 6.5 6 0.4 IU/mL, II; P , 0.0001 by analysis of
as a risk factor for the development and/or progression ofvariance). The ACE genotype independently influences serum
ACE levels and accounts for approximately 14% of its varia- several cardiovascular diseases, including left ventricular
tions (F 5 26.7, r 2 5 0.1393, df 1 to 214, P , 0.0001). Patients hypertrophy (LVH) [5–7] and ischemic heart disease
with DD and ID genotypes showed higher levels of ACR (1.59 6 [8–10], carotid atherosclerosis [11], cerebrovascular dis-0.2, DD 1 ID; 0.8 6 0.2 mg/mmol, II; P , 0.006 by ANOVA)
ease [12], as well as diabetic [13] and nondiabetic renaland bigger LVMI (124.1 6 2.3, DD 1 ID vs. 117.8 6 3.6
g/m2, II; P , 0.01 by ANOVA). No differences in the preva- disease [14], although some studies have yielded con-
lence and degree of target organ damage (TOD) were found flicting results. Similarly, an association has also been
reported among the M235T angiotensinogen (AGT)
gene polymorphism, plasma AGT levels [3, 15], and aKey words: renin-angiotensin-aldosterone system, cardiovascular dis-
ease, blood pressure, microalbuminuria, ACE gene. number of unfavorable clinical features such as early
onset of essential hypertension [16], coronary heart dis-
Received for publication March 26, 1999
ease [17], higher blood pressure levels in patients withand in revised form July 22, 1999
Accepted for publication September 9, 1999 diabetic nephropathy [18], and faster progression toward
end-stage renal disease in patients with IgA nephropathyÓ 2000 by the International Society of Nephrology
561
Pontremoli et al: RAAS genes and hypertensive organ damage562
[19]. Finally, a variant in the gene encoding subtype 1 complete physical examination and routine biochemical
analyses of blood and urine, as well as an assessmentof the angiotensin II type 1 receptor (AT1R), correspond-
ing to an adenine to cytosine (A!C) transversion at of the presence and extent of target organ damage. A
diagnosis of essential hypertension was made in all casesnucleotide position 1166 of the mRNA sequence has
been described and reported to be associated with essen- by the attending physician, and additional testing was
performed only when signs or symptoms suggesting sec-tial hypertension [20] and vascular stiffness [21].
The RAAS plays an important role in the develop- ondary hypertension were present. Hypertension was
defined according to fifth Joint Committee on Detection,ment of hypertensive end-organ damage not only as a
key regulator of both blood pressure and sodium homeo- Evaluation and Treatment of High Blood Pressure crite-
ria as an average blood pressure $ 140/90 mm Hg onstasis, but also as a modulator of vascular tone and struc-
ture and of cardiac and renal tissue remodeling [22]. at least three different occasions or by the presence of
antihypertensive treatment. Twenty-four–hour urinaryThese effects are primarily mediated by the final product
of its enzymatic cascade, that is, angiotensin II, which has collection was obtained from each subject on the day
prior to the study to assess dietary sodium intake. Allbeen shown to promote cellular growth, and interstitial
matrix deposition by multiple mechanisms [23]. The im- patients were on a free, salt-unrestricted diet at the time
of the study. They had never been treated for hypertensionportance of the RAAS in the development of renal and
cardiovascular damage is also supported by several stud- (N 5 173, 80%) or had been taken off therapy at least
four weeks prior to the study (N 5 42, 20%). On theies, pointing out the beneficial effect that inhibiting this
system has on the development and progression of these study day, blood pressure was measured on the right arm
by a trained nurse, with the patient in the sitting positioncomplications [24].
Thus, studying the potential connections between ge- after a five-minute rest, with a mercury sphygmomanome-
ter (cuff size 12.5 3 40 cm). The systolic and diastolicnetic variants of the RAAS components, which might
influence the local availability of angiotensin II, and tar- blood pressures were read to the nearest 2 mm Hg. The
disappearance of Korotkoff’s sounds (phase V) was theget organ damage is of great importance and could pro-
vide a useful clinical tool not only in the stratification criterion for diastolic blood pressure. The lowest of three
consecutive readings was recorded. Body mass indexof cardiovascular risk, but also in devising therapeutic
strategies in hypertensive patients. Previous studies by (BMI) was calculated using the formula: BMI 5 weight
(kg)/height (m2). Creatinine, blood urea nitrogen, elec-ourselves [25] and other authors [26] indicate that hyper-
tensive patients with the ACE DD polymorphism show trolytes, uric acid, triglycerides, total and high-density
lipoprotein (HDL) cholesterol, and other standardan increased prevalence of microalbuminuria, which is
a well-established, integrated marker of end organ chemistry evaluations were performed on serum ac-
cording to routine methods. Low-density lipoproteindamage.
The present study was therefore set up to evaluate (LDL) cholesterol was calculated using Friedewald’s for-
mula [27], and creatinine clearance (CCr) was calculatedthe relationship between genetic RAAS polymorphisms,
namely ACE I/D, AGT M235T, and AT1R A1166C, and using Cockroft’s formula [28]. Serum ACE activity was
measured in duplicate by the colorimetric method basedearly signs of cardiovascular damage in patients with
essential hypertension. on the quinoneimine dye produced from the substrate
p-hydroxyhippuryl-l-histidyl-l-leucine [29].
A family history of hypertension was ascertained by
METHODS
means of a standardized questionnaire and was defined
Patients as a diastolic blood pressure of greater than 90 mm Hg
or blood pressure elevation requiring antihypertensiveFrom January 1996 to January 1997, 215 consecutive
patients with essential hypertension attending the outpa- therapy occurring in a parent or sibling. Smoking was
graded using a five-point scale: nonsmoker, ex-smoker,tient clinic of our department were asked to take part
in this clinical study, which was approved by the ethical smoking 1 to 14 g/day, smoking 15 to 25 g/day, or smoking
more than 25 g/day (1 cigarette 5 1 g).committee of our institution. Patients with neoplastic,
hepatic, and/or renal disease, chronic heart failure
Assessment of RAAS genotypes(NYHA class III and IV), diabetes mellitus, renal failure
(defined as serum creatinine $124 mmol/L males, $106 DNA was isolated from frozen whole blood containing
ethylenediaminetetraacetic acid (EDTA) as an anticoag-mmol/L females), severe obesity (defined as body weight
.150% of ideal body weight according to the 1983 Met- ulant by a standard salting-out procedure and resus-
pended in a TE (10 mmol/L Tris/1 mmol/L EDTA, pHropolitan Life Insurance Company tables), disabling dis-
eases such as dementia, or inability to cooperate were 7.6) buffer. Genomic DNA (0.25 mg) was amplified by
the polymerase chain reaction in a 50 mL reaction mix-excluded from the study. Written informed consent was
obtained from each participant. All patients underwent ture containing 10 mmol/L Tris-HCl, pH 8.8, 50 mmol/L
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KCl, 1.5 mmol/L MgCl2, 0.1% Triton X-100, 200 mmol/L 63 normal subjects recruited from among the staff of our
hospital. To account for differences in basal creatinineeach of dATP, dCTP, dGTP, and dTTP, 0.12 mmol/L
each primer, and 0.5 U thermostable DNA polymerase excretion rates and BMI, different criteria were used to
define microalbuminuria in men (ACR between 2.38(Dynazyme, Espoo, Finland). The primer pairs used and
the annealing temperatures were the following: for the and 19) and women (ACR between 2.96 and 20). These
criteria proved to have good sensitivity and specificityACE I/D polymorphism, forward 59CTGGAGACCAC
TCCCATCCTTTCT39 and reverse 59GATGTGGCCA for the detection of an albumin excretion rate between
TCACATTCGTCAGAT39, 588C, which amplify the in- 20 and 200 mg/min [32]. The intra-assay and interassay
tron 16 region where the I/D fragment is located [30] variabilities of the method in our laboratory were 4.5
and, to avoid ID/DD mistyping, a pair of primers that and 6.1%, respectively.
produce an amplified product only in the presence of
Echocardiographythe insertion [9], forward 59TGGGACCACAGCGCC
CGCCACTAC39 and reverse 59TCGCCAGCCCTCC All echocardiographic studies were performed using
CATGCCCATAA39, 678C; for the AGT M235T poly- an Acuson XP-128 ultrasound machine. Echocardio-
morphism, forward 59CAGGGTGCTGTCCACACTG grams were obtained at rest with patients supine in the
GACCCC39 and reverse 59CCGTTTGTGCAGGGCC left lateral position, using standard parasternal and apical
TGGCTCTCT39, 678C; for the AT1 receptor, forward views. The overall monodimensional left ventricular
59AGAAGCCTGCACCATGTTTTGAG39 and reverse measurements and the bidimensional (apical four and
59CCTGTTGCTCCTCTAACGATTTA39, 618C. Am- two chamber) views were obtained according to the rec-
plification was obtained after the following steps were ommendations of the American Society of Echocardiog-
carried out: five minutes of denaturation at 958C, fol- raphy [33, 34]. All tracings were obtained and read by
lowed by 30 one-minute cycles at 948C, one minute at a single observer who was blinded to the clinical charac-
annealing temperature, and two minutes of DNA synthe- teristics of the patients under observation. Left ventricu-
sis at 728C, followed by 10 minutes at 728C. In any given lar mass was derived using the formula described by
set of reactions, a negative control containing no genomic Devereux et al [35]:
DNA and a positive control of known genotype were
LV mass (grams) 5 0.80 3 1.04 [(VSTd 1 LVIDdalways included. For the AGT M235T polymorphism,
primer-induced restriction analysis with AspI enzyme 1 PWTd)3 2 (LVIDd) 3] 1 0.6
was performed as previously reported [31]. The AT1-
where VSTd is ventricular septal thickness at the endreceptor A1166C polymorphism was assayed by restric-
diastole, LVIDd is the LV internal dimension at thetion analysis of the PCR product with the DdeI enzyme
end diastole, and PWTd is left ventricular posterior wall[20]. All samples were visualized after electrophoresis
thickness at the end diastole. Left ventricular mass wason a 2% agarose gel and ethidium bromide staining.
corrected for body surface area (LVMI) and was ex-Genotyping was performed in a blinded fashion.
pressed in units of g/m2. The presence of LVH was de-
Albuminuria fined for LVMI $ 125 g/m2 in either gender [36, 37]. No
patient showed dyssynergic areas that would invalidateUrinary albumin excretion was evaluated at the end
the theoretical assumptions behind the cardiac mass cal-of the wash out period, if any, as the albumin-to-creati-
culations.nine ratio (ACR) on three nonconsecutive first-morning
samples in the presence of a negative urine culture.
Common carotid ultrasonographic scanWhenever a positive urine culture was found, urine sam-
The intima plus media thickness (IMT) of both carotidples were discarded, appropriate antibacterial treatment
arteries was evaluated by a high-resolution ultrasono-instituted, and collections for albuminuria repeated only
graphic (US) scan as described by Kawagishi et al [38].after a second culture tested negative. The ACR was
Carotid arteries were investigated in the longitudinal andcalculated as urine albumin concentration (mg/L)/urine
the transverse projections by high-resolution real-timecreatinine concentration (mmol/L). Creatinine levels
ultrasonography using a 10 MHz in-line duplex Diasonicwere determined by the routine Jaffe reaction and albu-
Spectra System. The carotid artery was scanned at themin concentration by a commercially available radioim-
bifurcation and at the common carotid artery (CCA).munoassay kit (Sclavo, Cinisello). The average (arithme-
At each longitudinal projection, the far-wall IMT, astic mean) of three urine collections was taken as the ACR
defined by Weldelhag, Wiklund, and Wikstrand [39], wasfor each patient. Normal values of albumin excretion, as
measured at the distal end of the CCA, 10 mm caudallypreviously defined in our laboratory, were obtained by
to the point where the near and far walls lose theirsimultaneously measuring both the albumin excretion
parallel configuration. Carotid plaque was defined asrate in timed overnight urine collections and the ACR
in first-morning urine samples within the same group of IMT . 1.3 mm. IMT was always measured on the CCA
Pontremoli et al: RAAS genes and hypertensive organ damage564
Table 1. Clinical characteristics of 215 patientsoutside the plaque, if any was present. Each measure-
with essential hypertension
ment was calculated taking the averages of three read-
Rangeings.
N men/women 133/82
SBP mm Hg 16061.1 125–230Retinal vascular changes
DBP mm Hg 10360.6 80–140
The presence, type, and extent of hypertensive reti- MBP mm Hg 12260.6 103–163
Age years 4860.6 21–65nopathy were investigated in a darkened room and under
BMI kg/m2 2660.2 17–38pupil dilation. Direct ophthalmoscopy was carried out
Family history of Ht % 68
with a halogen ophthalmoscope. The first arteriovenous Duration of disease mos 5163.5 2–240
Serum glucose mg/dL 9060.8 62–115crossing at least one disc in diameter from the disc in
Serum uric acid mg/dL 5.260.1 1.8–9.4each quadrant was selected and assessed. Each quadrant
Serum creatinine mg/dL 0.960.01 0.5–1.4
of the fundus was photographed by means of a Zeiss Creatinine clearancea mL/min 8761.6 54–167
Triglycerides mg/dL 12664.9 39–369fundus camera with a 308 field. Photographic slides were
Total cholesterol mg/dL 21563 102–332projected and evaluated by the same ophthalmologist
LDL cholesterol mg/dL 13863 9–245
who was unaware of the patients’ clinical data. Retinal HDL cholesterol mg/dL 5161.1 21–100
Smokers % 61features sought were venule nipping, venule deviation,
ACR mg/mmol 1.5360.2 0.1–19and light reflex change at all clearly visualized crossings
Prevalence of Mib % 14
with comparably sized arterioles at least one disc in diam- LVMI g/m2 12362 48–213
LVHc % 46eter from the disc. The mean ratio of diameters of equiva-
Carotid IMT mm 0.6860.02 0.3–1.25lent order arterioles and venules in each quadrant was
Retinal changes % 74
measured, and the presence of focal arteriolar nar-
Data are mean 6 sem. Abbreviations are: Ht, hypertension; Mi, microalbumi-rowing, hemorrhages, exudates, and papilledema was nuria; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy as
evaluated by echocardiogram; IMT, intima plus media thickness; MBP, meansought. Retinal lesions were classified according to the
blood pressure.Keith–Wagener–Barker classification [40]. a Calculated using Cockroft’s formula [(1402age) · lean body mass (kg)/(serum
creatinine · 72)], in women the value was further multiplied by 0.85
Statistical analysis
All data are expressed as mean 6 sem. Differences
among variables were assessed using the appropriate
clustering procedure is to classify patients in clustersstatistical test based on the underlying distribution of the
with the smallest within-group variability and the biggestvariables [41]. One-way analysis of variance (ANOVA)
between-group variability for any given set of variables.with the Bonferroni test or Tukey multiple comparison
Patients within the same cluster show similar values forpost-test was used to analyze data from patients with
the variables taken into consideration, while differingdifferent genotypes and with/without organ damage.
from patients in the other cluster for those same vari-Variables found to deviate from normality were either
ables. The algorithm will start with k random clusters,log transformed or a nonparametric test (Kruskal-Wallis)
and then move cases in and out of clusters in an attemptwas applied. Relationships among variables were as-
to (a) minimize variability within clusters and (b) max-sessed using linear regression analysis and Pearson’s cor-
imize variability between clusters. This is analogous torelation coefficient. Comparisons of proportion between
“ANOVA in reverse” in the sense that the significancegroups were performed using the chi-square test. Multi-
test in ANOVA evaluates the between-group variabilityple regression analysis was performed to assess the inde-
against the within-group variability when computingpendent contribution of several variables, including
the significance test for the hypothesis that the meansRAAS polymorphisms. The relationship between gene
in the groups are different from each other. To evaluatepolymorphism and organ damage was evaluated taking
the appropriateness of classification, the within-clusterinto consideration various models of inheritance (addi-
variability (small if the classification is good) is comparedtive, dominant, and recessive). Grouping of heterozy-
gotes and homozygotes for I/D polymorphism was per- with the between-cluster variability (large if the classifi-
formed to evaluate the relationship of the D allele with cation is good); that is, a standard between-group analy-
quantitative variables such as ACR and LVMI according sis of variance for each variable is performed [42]. All
to a dominant model of inheritance (for example, with statistical analyses were performed using SPSS, Release
scores of 0 for II and 1 for ID and DD combined). 6.1. A P , 0.05 was considered statistically significant.
Multivariate (k-mean cluster) analysis was performed
on the entire cohort of patients to identify subgroups
RESULTS(clusters) of patients on the basis of the presence and
Clinical characteristics of study patients are reportedseverity of target organ damage and various patterns of
RAAS gene polymorphisms. The goal of the K-means in Table 1. The prevalence of different genetic polymor-
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phisms of the RAAS genes in our study patients was the
following: DD 32, ID 53, II 15% for the ACE gene; MM
28, MT 49, TT 23% for the AGT gene; and AA 50, AC
45, CC 5% for the AT1R gene. All genotypes distribu-
tions were in Hardy–Weinberg equilibrium (Table 1).
There was an overall frequency of 58% for the D allele
and 42% for the I allele of the ACE gene, 52 and 48%
for M and T alleles at position 235 of the AGT gene,
and finally 72 and 28% for A and C at position 1166 of
the AT1R gene. All of these calculations compare closely
with those of a control group of healthy, volunteer blood
donors of our hospital (N 5 56, age 51 6 0.9; ACE gene:
DD 30, ID 54, II 16%; AGT gene: MM 26, MT 50, TT
24%; AT1R gene: AA 48, AC 46, CC 6%), as well as
with other Caucasian populations [42].
There were no differences in age, prevalence of family
history for hypertension, current smokers, known dura-
tion of disease, BMI, blood pressure, serum glucose, uric
acid, and lipid profile when patients were grouped on
the basis of the three RAAS genotypes (data not shown).
The overall prevalence of end organ damage, namely
microalbuminuria, retinal vascular changes, and LVH
was 14, 74, and 46%, respectively. The overall prevalence
of carotid plaque was 25%.
Serum levels of ACE were higher in DD as compared
with ID and II patients (10.2 6 0.5, DD; 8.2 6 0.3, ID;
6.5 6 0.4 IU/mL, II; P , 0.0001 by ANOVA), as was
expected on the basis of genetic codominance. Multiple
linear regression analysis showed that the ACE genotype
significantly influences serum ACE levels and accounts Fig. 1. Urinary albumin excretion (A) and left ventricular mass index
(B) in hypertensive patients with and without the D allele of the angio-for approximately 14% of its variations (F 5 26.7, r 2 5
tensin converting enzyme (ACE) gene. P , 0.01 for albumin-to-creati-0.145, df 1 to 214, P , 0.0001). nine ratio (ACR) and P , 0.01 for left ventricular mass index (LVMI).
Patients with the DD genotype showed significantly Data are mean 6 sem.
higher ACR levels than II patients (1.8 6 0.4, DD; 0.8 6
0.2 mg/mmol, II; P 5 0.03). An association of the D
allele with higher urinary albumin excretion was also
Overall, no difference in the prevalence and degreeevident when pooled data from patients with the D allele
of different signs of target organ damage was found when(DD 1 ID) were compared with II patients (1.59 6 0.2,
the patients’ characteristics were analyzed on the basisDD 1 ID; 0.8 6 0.2 mg/mmol, II; P , 0.01 by analysis
of M/T polymorphism both when considering the threeof variance; Fig. 1A).
genotypes separately and when heterozygotic patientsNo difference was found in the prevalence of LVH,
were grouped either with MM or TT patients.evaluated either by electrocardiogram (ECG) or by
No association was detected between A/C polymor-echocardiogram (data not shown), in patients with differ-
phism and the presence and degree of end organ damageent genotypes of the ACE gene. However, patients with
in the study population, except for a greater LVMI inDD and ID genotypes showed significantly higher LVMI
patients with the AC and CC genotypes, as comparedas compared with II patients (124.1 6 2.3, DD 1 ID vs.
with those with the AA genotype (P , 0.05). However,117.8 6 3.6 g/m2, II; P , 0.01 by ANOVA; Fig. 1B).
this difference was largely due to age differences be-Furthermore, when data were analyzed on the basis of
tween the two groups, as indicated by results of ANOVALVMI, patients in the top quartile showed a greater
performed on LVMI by the AT1R genotype, taking ageprevalence of the D allele as compared with the rest of
as a covariate (covariate: age, F 15.41, P , 0.001; mainthe study population (68 vs. 54%, P 5 0.016, OR 5 1.85,
effect: AT1R, F 2.499, P 5 0.116).CI, 1.13 to 3.03). No association was found between ACE
To further investigate the relationship between combi-genotypes and either the prevalence of retinal vascular
nations of RAAS polymorphisms and target organ dam-changes or the degree of common carotid intima plus
media thickness. age, k-means cluster analysis was applied to data from
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the entire study population. Two subgroups of patients findings, showing that a significant part of plasma ACE
levels are under genetic control, confirm those by Rigatwere identified (cluster n8 1, N 5 70 and cluster n8 2,
N 5 57), differing significantly from each other by the et al [1], even though in this study the magnitude of
variations in serum ACE activity accounted for by I/Dpresence and severity of several features of target organ
damage (that is, albuminuria, carotid IMT, and LVMI), polymorphism is considerably lower.
Data reported here confirm and extend earlier prelimi-as well as by patterns of RAAS gene polymorphisms.
Besides showing higher blood pressure levels and BMI nary reports by our group [25] and others [26], indicating
that the ACE DD polymorphism is a risk factor for(P , 0.05), patients with more severe involvement of
target organs were more likely to carry a combination microalbuminuria and possible later development of
clinically relevant hypertensive renal damage. The rela-of the ACE D, AGT T, and AT1R C alleles (P , 0.05
for each one of the variables examined by multimethod, tionship between ACE I/D polymorphism and left ven-
tricular mass is a somewhat more controversial issue.between-group ANOVA, and contrast analysis). The re-
sults not only show that different signs of end organ Although some cross-sectional studies failed to detect
any association between mutations in the ACE gene anddamage cluster within the same subgroup of patients but
also, and most intriguingly, that subclinical cardiovascu- echocardiographically determined LVMI, a recent study
performed on a group of twins demonstrated that a sig-lar damage tends to be associated with potentially unfa-
vorable patterns of the RAAS genes. nificant quantity of LVM variation is under the influence
of the ACE gene [46]. These discrepancies are likely
due, at least in part, to the heterogeneity of the genetic
DISCUSSION
background of some study populations and sometimes
The RAAS genes are potential etiological candidates to inadequate sample size or to differences in clinical
for cardiovascular damage because through modulation characteristics (that is, hypertensive and normotensive
of both circulating and tissue actions of angiotensin II, subjects). Indeed, a recent review of the literature indi-
they might exert a significant effect on vascular remodel- cates that the ACE gene polymorphism may be a risk
ing. Our results show that the ACE I/D polymorphism factor for the development of LVH [45].
is associated to silent end-organ damage in patients with The AGT locus on chromosome 1q has been impli-
essential hypertension, namely increased urinary albu- cated as a candidate region for blood pressure-determin-
min excretion and left ventricular mass index (LVMI). ing genes in several studies. However, other studies have
Furthermore, this study suggests that potentially unfa- failed to confirm any association between the M235T
vorable combinations of RAAS polymorphisms such as polymorphism and the hypertensive phenotype [47].
ACE DD, AGT TT, and AT1R AC/CC could synergisti- Nevertheless, it has been demonstrated that this poly-
cally affect the development of hypertensive-atheroscle- morphism is a marker for AGT production, with carriers
rotic cardiovascular disease. Although the link between of the T235 variant showing, on average, higher plasma
these RAAS gene polymorphisms and the development levels of AGT [48]. Furthermore, the homozygosity for
of cardiovascular disease remains elusive, the observa- the T allele might be clinically relevant because these
tion that polymorphisms in the ACE and AGT genes patients have been reported to show greater blood pres-
act as markers for interindividual variations in the sure decreases when treated with ACE-I, thus suggesting
plasma and possibly cellular levels of their respective that differences in plasma AGT levels might affect the
protein products [2, 16] suggests a mechanism by which degree of the RAAS activation and in turn influence
genotype might have a bearing on the physiology of the the formation rate of angiotensin II [49]. Our study,
renin-angiotensin axis. however, failed to demonstrate a direct association of
Several studies have shown an association between the T allele with any hypertensive end-organ damage
ACE DD and ID genotypes and a large series of cardio- taken into consideration, thus confirming and expanding
vascular diseases ranging from ischemic heart disease the previous report by Fernandez-Llama et al [47].
and LVH to cerebral and peripheral vascular disease, as The AT1R A/C polymorphism is located in the 39 un-
well as to the susceptibility and rate of progression of translated region of the gene [20] and is apparently a
renal damage [44]. However, some other studies failed nonfunctional mutation. However, it may be linked to
to demonstrate a significant association between genetic an unidentified functional mutation in the AT1R gene
variations and clinically relevant end points [45]. or in another strictly linked gene that plays a major role
Although observational studies such as this one cannot in the development or progression of vascular damage
be used to define pathophysiological mechanisms, it is [50]. After an initial report by Tiret et al indicating that
reasonable to assume that the influence the ACE gene this polymorphism had a synergistic effect with ACE DD
has on hypertensive target organ damage might be medi- genotype in conveying an increased risk for myocardial
ated by genotype-dependent differences in renin-angio- infarction [51], Benetos et al suggested that it may be
responsible for increased aortic vascular stiffness, whichtensin system activity, possibly at the tissue level. Our
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Table 2. Cluster analysis of target organ damage and renin-angiotensin-aldosterone (RAAS) gene polymorphisms
Descriptive statistics
Analysis of varianceCluster n8 1 (N 5 70) Cluster n8 2 (N 5 57)
Variable Mean SD Variance Mean SD Variance Between SS Within SS F P
ACR 0.75157 1.27848 1.63452 2.8493 4.15938 17.3004 138.251 1081.6 15.9775 0.000109
IMT 0.63786 0.17413 0.03032 0.73158 0.21705 0.04711 0.27596 4.73034 7.29236 0.007885
LVMI 101.101 15.0482 226.448 144.189 17.9137 320.901 58329 33595.4 217.028 0.00000
ACE 0.87143 0.33714 0.11366 6.14035 22.3211 498.23 872.193 27908.7 3.90645 0.050303
AGT 0.67143 0.47309 0.22381 6.05263 22.3434 499.229 909.762 27972.3 4.06546 0.045912
AT1R 0.45714 0.50176 0.25176 7.45614 25.6543 658.145 1539.01 36873.5 5.21719 0.024052
Among the entire study population, two subgroups of patients were identified (cluster n81 and n82), differing significantly from each other by the presence and
severity of several features of target organ damage (that is, albuminuria, carotid IMT and LVMI) as well as by patterns of RAAS gene polymorphisms (P , 0.05
for each one of the variables examined by multimethod, between group ANOVA, and contrast analysis). Degrees of freedom are 1 to 125. Abbreviations are: ACR,
albumin-to-creatinine ratio; IMT, intima plus media thickness; LVMI, left ventricular mass index; ACE, angiotensin converting enzyme; AGT, angiotensinogen;
AT1R, angiotensin II type 1 receptor antagonist.
can be selectively attenuated by treatment with ACE-I factors could determine the development of target organ
damage in essential hypertension.[52]. Subsequently, it was reported that this polymor-
Although these results must be taken with cautionphism contributes to blood pressure variations [53] and
because of the small sample size and potential bias inis involved in the development of coronary artery steno-
the selection of patients, from a clinical perspective, theysis [54] and LVH in normotensive subjects [55]. How-
imply that genotyping for the RAAS genes could becomeever, in a study of 212 subjects randomly selected from
a useful tool in the clinical process of cardiovascularthe general population, Castellano et al failed to detect
risk stratification and possibly in planning therapeuticany relationship between AT1R A/C genotypes and ca-
strategies for hypertensive patients.rotid wall thickness or left ventricular mass [56]. Accord-
ingly, our data do not support a major role for this genetic
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